Pamoic Acid
Pamoic acid, 99%
CAS: 130-85-8 Molecular Formula: C23H16O6 Molecular Weight (g/mol): 388.38 MDL Number: MFCD00004079 InChI Key: WLJNZVDCPSBLRP-UHFFFAOYSA-N Synonym: pamoic acid,embonic acid,4,4'-methylenebis 3-hydroxy-2-naphthoic acid,pamosaeure,unii-7rrq8qz38n,2-naphthalenecarboxylic acid, 4,4'-methylenebis 3-hydroxy,7rrq8qz38n,pamoic acid 98+% hplc,4,4'-methylen-bis-3-hydroxy-2-naphthoesaeure PubChem CID: 8546 ChEBI: CHEBI:50186 IUPAC Name: 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid SMILES: OC(=O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C2C=CC=CC2=C1
Pamoic Acid, Spectrum™ Chemical
CAS: 130-85-8
Pamoic acid, 98+%
CAS: 130-85-8 Molecular Formula: C23H16O6 Molecular Weight (g/mol): 388.38 MDL Number: MFCD00004079 InChI Key: WLJNZVDCPSBLRP-UHFFFAOYSA-N Synonym: pamoic acid,embonic acid,4,4'-methylenebis 3-hydroxy-2-naphthoic acid,pamosaeure,unii-7rrq8qz38n,2-naphthalenecarboxylic acid, 4,4'-methylenebis 3-hydroxy,7rrq8qz38n,pamoic acid 98+% hplc,4,4'-methylen-bis-3-hydroxy-2-naphthoesaeure PubChem CID: 8546 ChEBI: CHEBI:50186 IUPAC Name: 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid SMILES: OC(=O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C2C=CC=CC2=C1
Pamoic Acid 96.0+%, TCI America™
CAS: 130-85-8 Molecular Formula: C23H16O6 Molecular Weight (g/mol): 388.38 MDL Number: MFCD00004079 InChI Key: WLJNZVDCPSBLRP-UHFFFAOYSA-N Synonym: pamoic acid,embonic acid,4,4'-methylenebis 3-hydroxy-2-naphthoic acid,pamosaeure,unii-7rrq8qz38n,2-naphthalenecarboxylic acid, 4,4'-methylenebis 3-hydroxy,7rrq8qz38n,pamoic acid 98+% hplc,4,4'-methylen-bis-3-hydroxy-2-naphthoesaeure PubChem CID: 8546 ChEBI: CHEBI:50186 IUPAC Name: 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid SMILES: OC(=O)C1=C(O)C(CC2=C3C=CC=CC3=CC(C(O)=O)=C2O)=C2C=CC=CC2=C1
Cayman Chemical PamoIc AcId 250g
A potent agonist of GPR35 orphan receptors (EC50 = 79 nM in a β-arrestin recruitment assay); induces GPR35 translocation from the plasma membrane to the cytoplasm (EC50 =22 nM); increases ERK1/2 phosphorylation in a concentration-dependent manner in U20S cells expressing human GPR35a; has antinociceptive effects in a mouse abdominal constriction model of visceral pain perception (ED50 = 40.5 mg/kg)
Medchemexpress LLC Pamoic acid | 130-85-8 | 99.7% | 388.38 | 1 ML
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. It exhibits neuroprotective and anti-inflammatory properties.
- Potent GPR35 agonist
- Exhibits neuroprotective properties
- Exhibits anti-inflammatory properties
Cayman Chemical PamoIc AcId 100g
A potent agonist of GPR35 orphan receptors (EC50 = 79 nM in a β-arrestin recruitment assay); induces GPR35 translocation from the plasma membrane to the cytoplasm (EC50 =22 nM); increases ERK1/2 phosphorylation in a concentration-dependent manner in U20S cells expressing human GPR35a; has antinociceptive effects in a mouse abdominal constriction model of visceral pain perception (ED50 = 40.5 mg/kg)
Medchemexpress LLC Pamoic acid (Embonic acid) | 130-85-8 | 99.7% | 388.38 | 1 G
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. It exhibits neuroprotective and anti-inflammatory properties. GPR35 activation by Pamoic acid may increase the phosphorylation of ERK1/2, which suppresses NF-κB-dependent inflammatory genes.
- Potent GPR35 agonist with an EC50 of 79 nM.
- Exhibits neuroprotective properties.
- Exhibits anti-inflammatory properties.
- Activates GPR35 to increase phosphorylation of ERK1/2.
- Suppresses NF-κB-dependent inflammatory genes.
- Reduces infarct size in a GPR35 dependent manner.
- Increases noninflammatory Ly-6CLo monocytes/macrophages in ischemic brain.
- Reduces neutrophil counts.
Medchemexpress LLC Pamoic acid (Embonic acid) | 130-85-8 | 99.7% | 388.38 | 100 G
Pamoic acid (Embonic acid) is a potent GPR35 agonist that demonstrates neuroprotective and anti-inflammatory properties. Its GPR35 activation may increase the phosphorylation of ERK1/2, which helps to suppress NF-κB-dependent inflammatory genes.
- Potent GPR35 agonist with an EC50 of 79 nM.
- Shows agonist activity at human GPR35 in CHO cell lines.
- Demonstrates neuroprotective activity in a mouse stroke model.
- Reduces infarct size in a GPR35-dependent manner.
- Increases noninflammatory Ly-6CLo monocytes/macrophages in the ischemic brain.
- Reduces neutrophil counts.
Medchemexpress LLC Pamoic acid | 130-85-8 | 99.7% | 388.38 | 50 G
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. It exhibits neuroprotective and anti-inflammatory properties, making it suitable for research into neurological and inflammatory diseases.
- Potent GPR35 agonist with an EC50 of 79 nM.
- Exhibits neuroprotective and anti-inflammatory properties.
- GPR35 activation may increase phosphorylation of ERK1/2, suppressing NF-κB-dependent inflammatory genes.
- Shows neuroprotective activity by activating GPR35, reducing infarct size in mouse stroke models.
- Increases noninflammatory Ly-6CLo monocytes/macrophages and reduces neutrophil counts in the ischemic brain.
Medchemexpress LLC Pamoic acid (disodium) | 6640-22-8 | 99.9% | 432.34 | 25 G
Pamoic acid (disodium) | 6640-22-8 | 99.9% | 432.34 | 25 G
Medchemexpress LLC Pamoic acid | 130-85-8 | 99.7% | 388.38 | 25 G
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. It exhibits neuroprotective and anti-inflammatory properties.
- Potent GPR35 agonist (EC50 of 79 nM).
- Exhibits neuroprotective properties.
- Exhibits anti-inflammatory properties.
- Reduces infarct size in a mouse model of stroke.
- Increases noninflammatory Ly-6CLo monocytes/macrophages and reduces neutrophil counts in the ischemic brain.
- GPR35 activation may increase ERK1/2 phosphorylation, initiating an anti-inflammatory signal by suppressing NF-κB-dependent inflammatory genes.
Medchemexpress LLC Pamoic acid | 130-85-8 | 99.7% | 388.38 | 10 G
Pamoic acid (Embonic acid) is a potent GPR35 agonist with an EC50 of 79 nM. It exhibits neuroprotective and anti-inflammatory properties.
- Potent GPR35 agonist with an EC50 of 79 nM.
- Exhibits neuroprotective and anti-inflammatory properties.
- Activates GPR35, which may increase the phosphorylation of ERK1/2, initiating an anti-inflammatory signal by suppressing NF-κB-dependent inflammatory genes.
- Has neuroprotective activity in a mouse model of stroke, reducing infarct size in a GPR35 dependent manner.
- Pamoic acid treatment results in a preferential increment of noninflammatory Ly-6CLo monocytes/macrophages in the ischemic brain along with reduced neutrophil counts.